During the past decade, Peking University First Hospital conducted 367 clinical trials. In the 10-year time frame, 367 clinical trials started and 40 clinical trials were completed, i.e. on average, 10.9% percent of trials that started reached the finish line to date. In the past 5 years, 205 clinical trials started and 30 clinical trials were completed. i.e. 14.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Peking University First Hospital" #1 sponsor was "Peking University First Hospital" with 101 trials, followed by "Janssen Research & Development, LLC" with 18 trials sponsored, "Hoffmann-La Roche" with 15 trials sponsored, "Pfizer" with 13 trials sponsored and "Beijing Friendship Hospital" with 13 trials sponsored. Other sponsors include 293 different institutions and companies that sponsored additional 167 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Peking University First Hospital" #1 collaborator was "Peking University First Hospital" with 36 trials as a collaborator, "Peking University People's Hospital" with 15 trials as a collaborator, "Peking Union Medical College Hospital" with 10 trials as a collaborator, "The Second Hospital of Hebei Medical University" with 9 trials as a collaborator and "Beijing Ditan Hospital" with 8 trials as a collaborator. Other collaborators include 572 different institutions and companies that were collaborators in the rest 323 trials.

According to Clinical.Site data, the most researched conditions in "Peking University First Hospital" are "Dexmedetomidine" (18 trials), "Chronic Hepatitis B" (9 trials), "Elderly" (9 trials), "Delirium" (8 trials) and "Hepatitis B" (8 trials). Many other conditions were trialed in "Peking University First Hospital" in a lesser frequency.

Most popular intervention types in "Peking University First Hospital" are "Drug" (331 trials), "Other" (53 trials), "Device" (31 trials), "Biological" (14 trials) and "Procedure" (13 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (96 trials), "Dexmedetomidine" (14 trials), "Dexamethasone" (11 trials), "Prednisone" (8 trials) and "placebo" (8 trials). Other intervention names were less common.

The vast majority of trials in "Peking University First Hospital" are 401 trials for "All" genders, 42 trials for "Female" genders and 14 trials for "Male" genders.

Currently, there are 184 active trials in "Peking University First Hospital". 16 are not yet recruiting, 116 are recruiting, 49 are Active, not recruiting, and 3 are Enrolling by invitation. In total, there were 176 completed trials in Peking University First Hospital, 2 suspended trials, and 14 terminated clinical trials to date.

Out of the total trials that were conducted in Peking University First Hospital, 34 "Phase 1" clinical trials were conducted, 72 "Phase 2" clinical trials and 143 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 61 trials, and there were also 82 trials that are defined as “Not Applicable".

Peking University First Hospital has several departments that took part in Clinical trials: "Peking University Insititute of Hematology, Peking University People's Hospital" - 18 trials, "Renal Division and Institute of Nephrology, Peking University First Hospital" - 5 trials, "Department of Radiation Oncology of Peking university third hospital" - 4 trials, "Pain medicine center of Peking University Third Hospital" - 4 trials, "General Surgery Department, Peking University Third Hospital" - 2 trials, "Peking Union Medical College Hospital; Pharmacy" - 2 trials